[ad_1]
(Seoul-Yonhap News) Sang-Don Park, a member of the Securities and Futures Commission of the Financial Services Commission, reviewed existing measures and changes to Samsung Bio Logics.
Koo plans to continue discussions at the regular meeting scheduled for October 18th. The Financial Supervisory Commission (FSS) initially announced that it would terminate its deliberations in the Supreme Court by the middle of this month, and the Supreme Court decided not to hold a special session.
According to the Ministry of Finance on April 4, Koo added that he was holding a regular meeting in the afternoon of the afternoon and was deliberating on the current prescribing of Samsung Biotech.
The deliberation took place on the 7th ordinary month, it is the fourth after the regular meeting.
In the morning morning, the Supreme Court of Korea (Samsung Securities) has dealt with other issues such as the imposition of a penalty for errors in the dividend policy of Samsung Securities Co.,
First, the Supreme Court of Korea (KOSEF) held a meeting on measures that had been discussed in the past.
The Financial Supervisory Service (FSS) estimates that Samsung Biotech has suddenly changed its subsidiary, Samsung BioEpice, from a subsidiary to a related company.
Although the Financial Supervisory Service (FSS) ruled that it was "misdemeanor" accounting, Samsung Biotech had the opportunity to exercise the option of Purchase (purchase option) of US Bioenergy due to the increase in the business value of its subsidiaries "He said.
Biogen is a multinational pharmaceutical company that co-founded Samsung Bio Epithegy with Samsung Biotech, which has a purchase option to take a 50% -1 stake in the creation of Samsung Biopies.
Indeed, Biogen will call options at the end of last month, and its shareholder ratio will rise to 49.9%. Samsung Biotech's stake in Samsung Bio was 94.6% and Biogen 5.4%.
At this meeting, the FSS also reviewed the new measures, with the FSS having prepared new amendments to the monitoring measure.
Koo pleaded with the Financial Supervisory Service (FSS) after the third meeting last month to request some supplementation of the monitoring measures. It was the order to refine Samsung Biotech's decision to change the judgment of Samsung Bio-Peace Control and revise the financial statement by year.
Indeed, Samsung Biotech must review the entire period from 2012 to 2014, since its creation in 2012 until there is more room for Samsung BioEpice to be counted in as a subsidiary rather than a subsidiary.
Proponents of the new measure are only reported to the Financial Supervisory Commission (FSS) and it is said that they have not proceeded to Samsung Bio.
As the FSS is preparing a new action plan, it is necessary to start again from the advance notification procedure for Samsung Bio, and it is necessary to take the time to review the new plan. action to guarantee the rights of the defense.
The Financial Supervisory Service reportedly failed to notify Samsung Biotech in advance of the preparation of new measures until the day before.
Given the circumstances of this time, the Supervisory Board will proceed to the deliberation of the Supreme Court Seems to be.
The Financial Supervisory Commission (FSC) has repeatedly announced that it would finalize the proceedings for the Supreme Court of Appeals until mid-February, but the final decision was made since the 18th.
The Supreme Court intends not to deliberate on the Supervisory Commission, which is an advisory body, with regard to the new measures. The reason is that discussions have already taken place on how to deal with accounting before 2014.
(end)
Source link
